Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation
The objective of the study was to determine the prevalence of bleeding during continuous-flow left ventricular assist device support and to identify potential mechanisms for those bleeding events. Bleeding is frequently reported with continuous-flow left ventricular assist devices and may result fro...
Uloženo v:
| Vydáno v: | Journal of the American College of Cardiology Ročník 56; číslo 15; s. 1207 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
05.10.2010
|
| Témata: | |
| ISSN: | 1558-3597, 1558-3597 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The objective of the study was to determine the prevalence of bleeding during continuous-flow left ventricular assist device support and to identify potential mechanisms for those bleeding events.
Bleeding is frequently reported with continuous-flow left ventricular assist devices and may result from anticoagulation coupled with bleeding diathesis such as acquired von Willebrand syndrome. Accordingly, the prevalence of coagulation abnormalities including laboratory assessment for von Willebrand syndrome, bleeding events during device support, and at heart transplantation were evaluated.
A retrospective study in all HeartMate II (HM II) (Thoratec Corp., Pleasanton, California) patients who underwent implantation between April 1, 2004, and August 1, 2009, was performed. Bleeding was defined as the need for transfusion >7 days after device insertion of 1 U of packed red blood cells. Transfusion at heart transplantation was compared with that in HeartMate XVE patients.
Seventy-nine HM II devices were implanted. Anticoagulation included warfarin in 68.3%, aspirin in 55.7%, and dipyridamole in 58.2% of the patients. Of the patients, 44.3% had bleeding episodes at 112 ± 183 days after left ventricular assist device implantation, with 50% experiencing an event within 2 months. Gastrointestinal bleeding was the most frequent event. At the index event, the international normalized ratio averaged 1.67 ± 0.53, and the platelet count was 237 ± 119 × 10(9)/l. Comparison of the transfusion requirements at heart transplantation of 35 HM II patients with 62 HeartMate XVE patients demonstrated twice the transfusion requirements in HM II patients (packed red blood cells, 6.3 ± 0.8 U vs. 3.8 ± 0.5 U; platelets, 12.5 ± 5.4 U vs. 8.6 ± 6.4 U; fresh frozen plasma, 9.6 ± 4.9 U vs. 4.9 ± 3.6 U; and cryoprecipitate, 4.3 ± 3.6 U vs. 2.2 ± 3.5 U; p < 0.05 for all). High molecular weight von Willebrand factor multimers were measured in 31 HM II patients and were reduced in all patients; 18 of these 31 (58%) patients had bleeding.
Patients with the HM II had a high incidence of bleeding events during device support and at heart transplantation. All HM II patients had reduced high molecular weight von Willebrand factor multimers. The role of these abnormalities in the high incidence of bleeding deserves further investigation. Furthermore, alterations in anticoagulation should be considered during device support and before surgery in patients supported with the HM II. |
|---|---|
| AbstractList | The objective of the study was to determine the prevalence of bleeding during continuous-flow left ventricular assist device support and to identify potential mechanisms for those bleeding events.
Bleeding is frequently reported with continuous-flow left ventricular assist devices and may result from anticoagulation coupled with bleeding diathesis such as acquired von Willebrand syndrome. Accordingly, the prevalence of coagulation abnormalities including laboratory assessment for von Willebrand syndrome, bleeding events during device support, and at heart transplantation were evaluated.
A retrospective study in all HeartMate II (HM II) (Thoratec Corp., Pleasanton, California) patients who underwent implantation between April 1, 2004, and August 1, 2009, was performed. Bleeding was defined as the need for transfusion >7 days after device insertion of 1 U of packed red blood cells. Transfusion at heart transplantation was compared with that in HeartMate XVE patients.
Seventy-nine HM II devices were implanted. Anticoagulation included warfarin in 68.3%, aspirin in 55.7%, and dipyridamole in 58.2% of the patients. Of the patients, 44.3% had bleeding episodes at 112 ± 183 days after left ventricular assist device implantation, with 50% experiencing an event within 2 months. Gastrointestinal bleeding was the most frequent event. At the index event, the international normalized ratio averaged 1.67 ± 0.53, and the platelet count was 237 ± 119 × 10(9)/l. Comparison of the transfusion requirements at heart transplantation of 35 HM II patients with 62 HeartMate XVE patients demonstrated twice the transfusion requirements in HM II patients (packed red blood cells, 6.3 ± 0.8 U vs. 3.8 ± 0.5 U; platelets, 12.5 ± 5.4 U vs. 8.6 ± 6.4 U; fresh frozen plasma, 9.6 ± 4.9 U vs. 4.9 ± 3.6 U; and cryoprecipitate, 4.3 ± 3.6 U vs. 2.2 ± 3.5 U; p < 0.05 for all). High molecular weight von Willebrand factor multimers were measured in 31 HM II patients and were reduced in all patients; 18 of these 31 (58%) patients had bleeding.
Patients with the HM II had a high incidence of bleeding events during device support and at heart transplantation. All HM II patients had reduced high molecular weight von Willebrand factor multimers. The role of these abnormalities in the high incidence of bleeding deserves further investigation. Furthermore, alterations in anticoagulation should be considered during device support and before surgery in patients supported with the HM II. The objective of the study was to determine the prevalence of bleeding during continuous-flow left ventricular assist device support and to identify potential mechanisms for those bleeding events.OBJECTIVESThe objective of the study was to determine the prevalence of bleeding during continuous-flow left ventricular assist device support and to identify potential mechanisms for those bleeding events.Bleeding is frequently reported with continuous-flow left ventricular assist devices and may result from anticoagulation coupled with bleeding diathesis such as acquired von Willebrand syndrome. Accordingly, the prevalence of coagulation abnormalities including laboratory assessment for von Willebrand syndrome, bleeding events during device support, and at heart transplantation were evaluated.BACKGROUNDBleeding is frequently reported with continuous-flow left ventricular assist devices and may result from anticoagulation coupled with bleeding diathesis such as acquired von Willebrand syndrome. Accordingly, the prevalence of coagulation abnormalities including laboratory assessment for von Willebrand syndrome, bleeding events during device support, and at heart transplantation were evaluated.A retrospective study in all HeartMate II (HM II) (Thoratec Corp., Pleasanton, California) patients who underwent implantation between April 1, 2004, and August 1, 2009, was performed. Bleeding was defined as the need for transfusion >7 days after device insertion of 1 U of packed red blood cells. Transfusion at heart transplantation was compared with that in HeartMate XVE patients.METHODSA retrospective study in all HeartMate II (HM II) (Thoratec Corp., Pleasanton, California) patients who underwent implantation between April 1, 2004, and August 1, 2009, was performed. Bleeding was defined as the need for transfusion >7 days after device insertion of 1 U of packed red blood cells. Transfusion at heart transplantation was compared with that in HeartMate XVE patients.Seventy-nine HM II devices were implanted. Anticoagulation included warfarin in 68.3%, aspirin in 55.7%, and dipyridamole in 58.2% of the patients. Of the patients, 44.3% had bleeding episodes at 112 ± 183 days after left ventricular assist device implantation, with 50% experiencing an event within 2 months. Gastrointestinal bleeding was the most frequent event. At the index event, the international normalized ratio averaged 1.67 ± 0.53, and the platelet count was 237 ± 119 × 10(9)/l. Comparison of the transfusion requirements at heart transplantation of 35 HM II patients with 62 HeartMate XVE patients demonstrated twice the transfusion requirements in HM II patients (packed red blood cells, 6.3 ± 0.8 U vs. 3.8 ± 0.5 U; platelets, 12.5 ± 5.4 U vs. 8.6 ± 6.4 U; fresh frozen plasma, 9.6 ± 4.9 U vs. 4.9 ± 3.6 U; and cryoprecipitate, 4.3 ± 3.6 U vs. 2.2 ± 3.5 U; p < 0.05 for all). High molecular weight von Willebrand factor multimers were measured in 31 HM II patients and were reduced in all patients; 18 of these 31 (58%) patients had bleeding.RESULTSSeventy-nine HM II devices were implanted. Anticoagulation included warfarin in 68.3%, aspirin in 55.7%, and dipyridamole in 58.2% of the patients. Of the patients, 44.3% had bleeding episodes at 112 ± 183 days after left ventricular assist device implantation, with 50% experiencing an event within 2 months. Gastrointestinal bleeding was the most frequent event. At the index event, the international normalized ratio averaged 1.67 ± 0.53, and the platelet count was 237 ± 119 × 10(9)/l. Comparison of the transfusion requirements at heart transplantation of 35 HM II patients with 62 HeartMate XVE patients demonstrated twice the transfusion requirements in HM II patients (packed red blood cells, 6.3 ± 0.8 U vs. 3.8 ± 0.5 U; platelets, 12.5 ± 5.4 U vs. 8.6 ± 6.4 U; fresh frozen plasma, 9.6 ± 4.9 U vs. 4.9 ± 3.6 U; and cryoprecipitate, 4.3 ± 3.6 U vs. 2.2 ± 3.5 U; p < 0.05 for all). High molecular weight von Willebrand factor multimers were measured in 31 HM II patients and were reduced in all patients; 18 of these 31 (58%) patients had bleeding.Patients with the HM II had a high incidence of bleeding events during device support and at heart transplantation. All HM II patients had reduced high molecular weight von Willebrand factor multimers. The role of these abnormalities in the high incidence of bleeding deserves further investigation. Furthermore, alterations in anticoagulation should be considered during device support and before surgery in patients supported with the HM II.CONCLUSIONSPatients with the HM II had a high incidence of bleeding events during device support and at heart transplantation. All HM II patients had reduced high molecular weight von Willebrand factor multimers. The role of these abnormalities in the high incidence of bleeding deserves further investigation. Furthermore, alterations in anticoagulation should be considered during device support and before surgery in patients supported with the HM II. |
| Author | Naka, Yoshifumi Jude, Brigitte Uriel, Nir Mancini, Donna Pak, Sang-Woo Jorde, Ulrich P Ennezat, Pierre-Vladimir Susen, Sophie Vincentelli, Andre Cappleman, Sarah |
| Author_xml | – sequence: 1 givenname: Nir surname: Uriel fullname: Uriel, Nir organization: Department of Medicine, College of Physicians and Surgeons, Columbia University, 622 West 168th Street, New York, NY 10032, USA – sequence: 2 givenname: Sang-Woo surname: Pak fullname: Pak, Sang-Woo – sequence: 3 givenname: Ulrich P surname: Jorde fullname: Jorde, Ulrich P – sequence: 4 givenname: Brigitte surname: Jude fullname: Jude, Brigitte – sequence: 5 givenname: Sophie surname: Susen fullname: Susen, Sophie – sequence: 6 givenname: Andre surname: Vincentelli fullname: Vincentelli, Andre – sequence: 7 givenname: Pierre-Vladimir surname: Ennezat fullname: Ennezat, Pierre-Vladimir – sequence: 8 givenname: Sarah surname: Cappleman fullname: Cappleman, Sarah – sequence: 9 givenname: Yoshifumi surname: Naka fullname: Naka, Yoshifumi – sequence: 10 givenname: Donna surname: Mancini fullname: Mancini, Donna |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20598466$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUMlOwzAUtBAIyvIDHJBvnFKctLaTY1WxSUhcQBwrLy-tK8dObaeIT-PvMKUgTvM0mpk3mlN06LwDhC5LMi5JyW7W47VQalyRTBA6ztQBGpWU1sWENvzw332CTmNcE0JYXTbH6KQitKmnjI3Q50xtBhNA4613-M1YCzIIp3H8cDr4DrBoEwSsvEvGDX6IRWv9O-5ArYQzSlisYWsU4Dj0vQ9ppwxGDgkiTh4LvDLLFe4DbIUFl4W-xdICaOOWWA_hG6x3yyK_6f5SviuIhNMKcDLdzpRyr9hb4ZJIxrtzdNQKG-Fij2fo9e72Zf5QPD3fP85nT4WiNU1FzZUG2iheallLqRmBRksm2HRSagKs5WpKJKk4NLypOAFFYCJ0TcUkOzmpztD1T24f_GaAmBadiQpsLgJ5jgWnjOWJWZOVV3vlIDvQiz6YToSPxe_a1Rf1EIqk |
| CitedBy_id | crossref_primary_10_1002_rth2_12226 crossref_primary_10_1161_CIRCRESAHA_119_313574 crossref_primary_10_1016_j_healun_2025_08_025 crossref_primary_10_1161_JAHA_120_018035 crossref_primary_10_1016_j_ccl_2018_06_006 crossref_primary_10_1097_MAT_0000000000000859 crossref_primary_10_1097_MAT_0000000000000612 crossref_primary_10_3233_BIR_15065 crossref_primary_10_1097_MAT_0000000000001942 crossref_primary_10_1177_03913988241286437 crossref_primary_10_1097_MAT_0000000000000734 crossref_primary_10_1111_jth_13497 crossref_primary_10_1007_s11897_016_0310_z crossref_primary_10_1038_s41598_024_71603_z crossref_primary_10_1016_j_cpcardiol_2023_101988 crossref_primary_10_1016_j_healun_2017_06_004 crossref_primary_10_7182_pit2013954 crossref_primary_10_1161_ATVBAHA_112_300522 crossref_primary_10_1016_j_gie_2017_05_018 crossref_primary_10_1016_j_tmrv_2014_12_001 crossref_primary_10_1007_s10047_020_01170_3 crossref_primary_10_1161_CIRCHEARTFAILURE_118_004899 crossref_primary_10_1016_j_jchf_2014_11_005 crossref_primary_10_1002_jac5_1313 crossref_primary_10_1055_a_1508_8230 crossref_primary_10_1097_MAT_0000000000000874 crossref_primary_10_1093_bja_aer512 crossref_primary_10_1097_MAT_0000000000000758 crossref_primary_10_1016_j_jacc_2010_12_007 crossref_primary_10_1161_CIRCRESAHA_117_310848 crossref_primary_10_1111_aor_13725 crossref_primary_10_1161_CIRCOUTCOMES_113_000556 crossref_primary_10_1016_j_jtcvs_2016_01_031 crossref_primary_10_1016_j_hoc_2012_01_002 crossref_primary_10_1016_j_bspc_2023_104640 crossref_primary_10_1016_j_cgh_2018_05_056 crossref_primary_10_1586_erd_11_9 crossref_primary_10_1093_ejcts_ezw348 crossref_primary_10_1097_HCO_0b013e3283438258 crossref_primary_10_1007_s10620_016_4123_4 crossref_primary_10_3390_ijms231810252 crossref_primary_10_1097_MAT_0000000000000624 crossref_primary_10_1111_jth_15784 crossref_primary_10_1053_j_jvca_2010_11_001 crossref_primary_10_1097_MAT_0b013e318272c320 crossref_primary_10_1016_j_ccl_2011_08_005 crossref_primary_10_1111_jth_13120 crossref_primary_10_1161_ATVBAHA_122_317517 crossref_primary_10_1007_s00398_018_0226_x crossref_primary_10_1007_s10047_012_0664_2 crossref_primary_10_1016_j_bpa_2017_06_004 crossref_primary_10_1136_neurintsurg_2018_014645 crossref_primary_10_1002_rth2_12150 crossref_primary_10_1007_s00059_015_4365_5 crossref_primary_10_1016_S0049_3848_16_30366_8 crossref_primary_10_1007_s00405_020_06127_z crossref_primary_10_1016_j_healun_2014_07_002 crossref_primary_10_1016_j_healun_2024_05_010 crossref_primary_10_1080_14779072_2018_1417039 crossref_primary_10_1161_CIRCHEARTFAILURE_111_963991 crossref_primary_10_1016_j_athoracsur_2012_01_087 crossref_primary_10_1097_PCC_0000000000002021 crossref_primary_10_1007_s10741_014_9458_3 crossref_primary_10_1111_jth_15889 crossref_primary_10_1053_j_semtcvs_2016_01_001 crossref_primary_10_1186_s13019_018_0703_z crossref_primary_10_1016_j_healun_2016_12_016 crossref_primary_10_1016_j_amjcard_2018_03_363 crossref_primary_10_1016_j_thromres_2017_09_006 crossref_primary_10_1007_s11936_010_0093_6 crossref_primary_10_2217_fca_2022_0054 crossref_primary_10_1097_MAT_0000000000000831 crossref_primary_10_1111_jth_13317 crossref_primary_10_1097_MAT_0000000000000954 crossref_primary_10_1161_CIRCULATIONAHA_111_060830 crossref_primary_10_1016_j_jacc_2019_01_051 crossref_primary_10_1016_j_healun_2016_05_019 crossref_primary_10_1016_j_athoracsur_2016_07_072 crossref_primary_10_5301_ijao_5000478 crossref_primary_10_1002_phar_2632 crossref_primary_10_1016_j_pcad_2011_06_002 crossref_primary_10_1093_eurjhf_hfs012 crossref_primary_10_1016_j_jtcvs_2018_07_081 crossref_primary_10_1002_ejhf_1284 crossref_primary_10_1007_s10620_016_4379_8 crossref_primary_10_1016_j_jacc_2013_05_089 crossref_primary_10_1016_j_jtcvs_2011_10_072 crossref_primary_10_1097_AIA_0000000000000375 crossref_primary_10_1177_0003134820945265 crossref_primary_10_1016_j_acvd_2020_03_017 crossref_primary_10_1016_j_anclin_2012_12_008 crossref_primary_10_1016_j_jacc_2010_11_026 crossref_primary_10_1007_s10620_014_3200_9 crossref_primary_10_1016_j_rec_2016_12_036 crossref_primary_10_3390_hearts5010008 crossref_primary_10_1016_j_hfc_2016_03_012 crossref_primary_10_3390_ijms26188776 crossref_primary_10_1007_s00464_018_6497_1 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000206 crossref_primary_10_1016_j_athoracsur_2014_04_027 crossref_primary_10_1007_s10741_013_9389_4 crossref_primary_10_1177_0267659113494963 crossref_primary_10_1007_s11936_013_0283_0 crossref_primary_10_1016_j_cardfail_2013_12_011 crossref_primary_10_1097_MAT_0000000000000680 crossref_primary_10_1016_j_jacc_2010_06_009 crossref_primary_10_1097_MAT_0000000000000329 crossref_primary_10_1182_blood_2015_10_636480 crossref_primary_10_1016_j_wneu_2019_08_211 crossref_primary_10_1007_s10047_013_0753_x crossref_primary_10_1111_aor_12351 crossref_primary_10_1586_17474086_2015_1060854 crossref_primary_10_1007_s10527_024_10423_x crossref_primary_10_1161_CIRCHEARTFAILURE_111_962613 crossref_primary_10_1055_s_0041_1726328 crossref_primary_10_1002_ehf2_13587 crossref_primary_10_1002_ehf2_14433 crossref_primary_10_1055_a_2487_6365 crossref_primary_10_1016_j_healun_2015_05_018 crossref_primary_10_1111_aor_12116 crossref_primary_10_1111_aor_13445 crossref_primary_10_1161_CIRCHEARTFAILURE_117_004500 crossref_primary_10_1016_j_healun_2018_03_002 crossref_primary_10_1097_MAT_0000000000001790 crossref_primary_10_1016_j_jchf_2015_07_011 crossref_primary_10_1016_j_pmrj_2018_05_027 crossref_primary_10_1097_HCO_0000000000000283 crossref_primary_10_1111_aor_12123 crossref_primary_10_1016_j_healun_2016_06_007 crossref_primary_10_1016_j_jtcvs_2015_09_065 crossref_primary_10_1016_j_cjca_2022_11_004 crossref_primary_10_1111_1742_6723_12171 crossref_primary_10_1007_s10741_020_10019_z crossref_primary_10_1097_MAT_0000000000000229 crossref_primary_10_1097_MAT_0000000000001317 crossref_primary_10_1111_aor_14549 crossref_primary_10_3390_fluids9070157 crossref_primary_10_3389_fsurg_2015_00042 crossref_primary_10_1111_aor_13456 crossref_primary_10_1007_s11886_018_0945_3 crossref_primary_10_1111_aor_14432 crossref_primary_10_1111_jocs_14620 crossref_primary_10_1161_CIRCHEARTFAILURE_110_959023 crossref_primary_10_1213_ANE_0000000000004220 crossref_primary_10_1007_s10047_019_01138_y crossref_primary_10_1016_j_medengphy_2011_04_010 crossref_primary_10_2217_fca_12_89 crossref_primary_10_1016_j_jacc_2015_10_028 crossref_primary_10_1016_j_joms_2020_05_019 crossref_primary_10_1097_HCO_0000000000000037 crossref_primary_10_1016_j_jacc_2015_04_039 crossref_primary_10_1097_MAT_0000000000000417 crossref_primary_10_1056_NEJMoa1800866 crossref_primary_10_1097_MAT_0000000000001623 crossref_primary_10_1186_s13019_015_0333_7 crossref_primary_10_1016_j_athoracsur_2016_06_112 crossref_primary_10_1111_acem_13964 crossref_primary_10_1016_j_healun_2015_12_027 crossref_primary_10_1002_ejhf_2327 crossref_primary_10_1097_CRD_0000000000000117 crossref_primary_10_1111_aor_14319 crossref_primary_10_1016_j_healun_2015_12_024 crossref_primary_10_1097_CRD_0000000000000235 crossref_primary_10_1016_j_jchf_2016_08_005 crossref_primary_10_1007_s11897_012_0127_3 crossref_primary_10_1111_aor_13594 crossref_primary_10_1111_aor_12382 crossref_primary_10_1152_japplphysiol_00416_2013 crossref_primary_10_1016_j_jtcvs_2014_04_009 crossref_primary_10_1002_clc_22096 crossref_primary_10_1053_j_jvca_2017_11_003 crossref_primary_10_1016_j_jacc_2013_08_1656 crossref_primary_10_1097_MAT_0000000000000887 crossref_primary_10_1056_NEJMoa1900486 crossref_primary_10_1126_scitranslmed_aah5533 crossref_primary_10_1016_j_jacc_2012_01_064 crossref_primary_10_1177_0391398818822267 crossref_primary_10_1111_jocs_13794 crossref_primary_10_1515_bmt_2017_0095 crossref_primary_10_1111_aor_14456 crossref_primary_10_1016_j_oooo_2014_04_010 crossref_primary_10_1097_HCO_0b013e328346ccf1 crossref_primary_10_1097_MAT_0000000000001886 crossref_primary_10_1053_j_jvca_2015_01_027 crossref_primary_10_1097_MAT_0000000000000433 crossref_primary_10_1016_j_healun_2015_06_018 crossref_primary_10_1016_j_jtcvs_2014_07_091 crossref_primary_10_1097_MAT_0b013e31829f9bb3 crossref_primary_10_1016_j_cardfail_2020_01_004 crossref_primary_10_1007_s10620_016_4386_9 crossref_primary_10_1007_s00063_014_0398_4 crossref_primary_10_1016_j_healun_2013_02_006 crossref_primary_10_1111_j_1600_0609_2011_01664_x crossref_primary_10_1016_j_amjcard_2019_03_038 crossref_primary_10_1016_j_jchf_2015_06_016 crossref_primary_10_1161_CIRCRESAHA_116_305046 crossref_primary_10_1016_j_bpa_2012_04_003 crossref_primary_10_1097_MAT_0000000000000541 crossref_primary_10_1016_j_gie_2014_09_032 crossref_primary_10_1016_j_healun_2021_06_003 crossref_primary_10_1371_journal_pone_0171029 crossref_primary_10_1016_j_metabol_2017_01_009 crossref_primary_10_1016_j_trsl_2017_10_006 crossref_primary_10_1097_MAT_0000000000000170 crossref_primary_10_1186_cc10098 crossref_primary_10_1016_j_jtcvs_2019_03_133 crossref_primary_10_1016_j_jtcvs_2014_09_031 crossref_primary_10_1097_MAT_0000000000001028 crossref_primary_10_1038_s41598_021_02833_8 crossref_primary_10_1097_HCO_0b013e328344b569 crossref_primary_10_1097_MAT_0000000000001021 crossref_primary_10_1016_j_ajem_2019_04_050 crossref_primary_10_1007_s11897_011_0050_z crossref_primary_10_1016_j_jacc_2018_02_075 crossref_primary_10_12998_wjcc_v10_i26_9192 crossref_primary_10_1016_j_jacc_2018_02_074 crossref_primary_10_1111_jth_13933 crossref_primary_10_3390_biomedicines11030757 crossref_primary_10_1097_MAT_0000000000000049 crossref_primary_10_1177_1076029620982374 crossref_primary_10_1002_phar_2016 crossref_primary_10_1093_ejcts_ezr312 crossref_primary_10_1111_trf_17351 crossref_primary_10_1093_ejcts_ezz165 crossref_primary_10_1136_bcr_2020_239053 crossref_primary_10_1080_17434440_2017_1409112 crossref_primary_10_1016_j_jtcvs_2011_03_029 crossref_primary_10_1097_CRD_0000000000000202 crossref_primary_10_1097_MAT_0000000000002250 crossref_primary_10_1016_j_hfc_2020_02_003 crossref_primary_10_1016_j_jtcvs_2014_10_026 crossref_primary_10_1080_1354750X_2019_1609089 crossref_primary_10_1053_j_jvca_2019_09_015 crossref_primary_10_1016_j_gie_2014_03_040 crossref_primary_10_1097_MAT_0000000000000077 crossref_primary_10_1177_1089253213506788 crossref_primary_10_1016_j_athoracsur_2012_02_035 crossref_primary_10_1007_s10047_022_01367_8 crossref_primary_10_1111_jgs_16105 crossref_primary_10_1016_j_healun_2012_02_032 crossref_primary_10_1016_j_jcv_2016_03_007 crossref_primary_10_1016_j_thromres_2019_10_012 crossref_primary_10_1016_j_bcmd_2020_102526 crossref_primary_10_1161_JAHA_117_005955 crossref_primary_10_1097_CRD_0000000000000212 crossref_primary_10_1016_j_wneu_2017_09_083 crossref_primary_10_1097_MAT_0000000000000061 crossref_primary_10_1097_MAT_0000000000001392 crossref_primary_10_1007_s00101_025_01565_y crossref_primary_10_3748_wjg_v23_i22_3945 crossref_primary_10_1007_s12328_015_0551_5 crossref_primary_10_1097_MAT_0000000000000069 crossref_primary_10_1097_MAT_0000000000002246 crossref_primary_10_1177_2150135111420888 crossref_primary_10_1182_blood_2010_11_297580 crossref_primary_10_3748_wjg_v22_i18_4559 crossref_primary_10_1016_j_cardfail_2014_08_010 crossref_primary_10_1016_j_hlc_2021_10_007 crossref_primary_10_3390_ijms25010288 crossref_primary_10_3389_fcvm_2023_1159894 crossref_primary_10_1213_ANE_0000000000001629 crossref_primary_10_1007_s10620_015_3743_4 crossref_primary_10_1016_j_jchf_2015_09_009 crossref_primary_10_1016_j_hoc_2021_07_005 crossref_primary_10_1016_j_healun_2014_05_005 crossref_primary_10_1007_s11886_015_0670_0 crossref_primary_10_1016_j_cardfail_2018_01_011 crossref_primary_10_1053_j_jvca_2013_05_019 crossref_primary_10_1016_j_cardfail_2019_01_012 crossref_primary_10_1097_MAT_0000000000000491 crossref_primary_10_1016_j_healun_2021_03_005 crossref_primary_10_1097_MAT_0000000000001224 crossref_primary_10_1016_j_healun_2012_02_015 crossref_primary_10_1016_j_ccl_2012_07_003 crossref_primary_10_1016_j_gie_2011_12_014 crossref_primary_10_1016_j_healun_2016_09_010 crossref_primary_10_1097_MAT_0000000000002317 crossref_primary_10_1016_j_healun_2020_03_001 crossref_primary_10_1111_jocs_16647 crossref_primary_10_1007_s10741_012_9303_5 crossref_primary_10_3389_fsurg_2015_00035 crossref_primary_10_1016_j_healun_2019_05_006 crossref_primary_10_1007_s10554_019_01562_4 crossref_primary_10_1186_s12872_016_0334_z crossref_primary_10_1111_aor_15013 crossref_primary_10_1378_chest_13_2645 crossref_primary_10_1007_s10047_019_01121_7 crossref_primary_10_1097_PCC_0000000000000757 crossref_primary_10_2215_CJN_05750515 crossref_primary_10_1097_MAT_0000000000000243 crossref_primary_10_1007_s00398_012_0937_3 crossref_primary_10_1007_s10741_023_10313_6 crossref_primary_10_1016_j_wneu_2015_12_061 crossref_primary_10_1016_j_cardfail_2015_08_005 crossref_primary_10_1016_j_healun_2013_10_005 crossref_primary_10_1186_s40463_018_0295_6 crossref_primary_10_1007_s12055_020_01010_2 crossref_primary_10_14423_SMJ_0000000000000938 crossref_primary_10_1007_s10741_021_10093_x crossref_primary_10_1016_j_healun_2019_05_004 crossref_primary_10_1111_jocs_16637 crossref_primary_10_1007_s12265_012_9360_0 crossref_primary_10_1007_s00134_011_2370_6 crossref_primary_10_1097_MAT_0000000000000390 crossref_primary_10_1016_j_jtcvs_2015_09_015 crossref_primary_10_1161_CIRCHEARTFAILURE_115_002296 crossref_primary_10_1111_j_1751_7133_2011_00219_x crossref_primary_10_1097_MAT_0000000000000157 crossref_primary_10_1097_MAT_0000000000000276 crossref_primary_10_1161_CIRCHEARTFAILURE_118_005082 crossref_primary_10_1016_S0049_3848_13_70003_3 crossref_primary_10_1213_ANE_0b013e318236b16a crossref_primary_10_17106_jbr_36_12 crossref_primary_10_1186_s13019_017_0587_3 crossref_primary_10_4137_CMC_S19708 crossref_primary_10_1016_j_healun_2020_01_1330 crossref_primary_10_1053_j_jvca_2014_02_015 crossref_primary_10_1007_s12028_018_0531_y crossref_primary_10_1007_s11010_017_3021_1 crossref_primary_10_1016_j_jacc_2012_07_052 crossref_primary_10_1097_MAT_0000000000000262 crossref_primary_10_1093_ejcts_ezy172 crossref_primary_10_1016_j_transproceed_2013_02_072 crossref_primary_10_1097_ACO_0000000000000083 crossref_primary_10_1016_j_cgh_2014_01_027 crossref_primary_10_1007_s00398_015_0039_0 crossref_primary_10_1016_j_thromres_2015_11_002 crossref_primary_10_1177_03913988211041639 crossref_primary_10_5301_IJAO_2011_8459 crossref_primary_10_1016_j_cpcardiol_2021_100940 crossref_primary_10_1097_HCO_0b013e328345af65 crossref_primary_10_1186_s13054_016_1235_3 crossref_primary_10_1007_s10047_020_01219_3 crossref_primary_10_1016_j_jtcvs_2016_03_014 crossref_primary_10_1080_24748706_2018_1468125 crossref_primary_10_1016_j_tcm_2024_11_004 crossref_primary_10_1016_j_healun_2011_01_703 crossref_primary_10_1016_j_athoracsur_2020_09_039 crossref_primary_10_1097_MAT_0000000000002189 crossref_primary_10_1016_j_healun_2012_11_010 crossref_primary_10_1016_j_rpth_2024_102431 crossref_primary_10_1016_j_cgh_2014_11_023 crossref_primary_10_1161_CIRCULATIONAHA_117_028303 crossref_primary_10_1016_j_mayocp_2014_01_004 crossref_primary_10_1177_0897190011431635 crossref_primary_10_1161_CIR_0b013e3182769a54 crossref_primary_10_3109_09537104_2014_948840 crossref_primary_10_1016_j_bpa_2012_01_003 crossref_primary_10_1053_j_jvca_2021_05_017 crossref_primary_10_1182_blood_2015_09_667642 crossref_primary_10_1097_HCO_0b013e328345af80 crossref_primary_10_1111_jth_13753 crossref_primary_10_3390_ijms23105303 crossref_primary_10_1213_ANE_0000000000002669 crossref_primary_10_3390_ijms22147414 crossref_primary_10_1016_j_healun_2013_12_002 crossref_primary_10_1016_j_healun_2013_08_013 crossref_primary_10_1053_j_jvca_2012_09_022 crossref_primary_10_1007_s00398_013_1050_y crossref_primary_10_1016_j_jacep_2016_03_009 crossref_primary_10_3389_fmed_2019_00007 crossref_primary_10_1093_ejcts_ezac421 crossref_primary_10_1111_j_1537_2995_2011_03500_x crossref_primary_10_1016_j_healun_2016_10_001 crossref_primary_10_1016_j_healun_2017_12_017 crossref_primary_10_1016_j_jchf_2016_10_007 crossref_primary_10_1097_MAT_0b013e31824363e7 crossref_primary_10_1136_heartjnl_2014_306789 crossref_primary_10_1161_CIRCHEARTFAILURE_118_005267 crossref_primary_10_1111_jocs_14060 crossref_primary_10_1002_advs_202003327 crossref_primary_10_1111_jocs_14062 crossref_primary_10_1016_j_amjms_2025_03_008 crossref_primary_10_1016_j_jacc_2011_02_025 crossref_primary_10_1097_MAT_0000000000001189 crossref_primary_10_1161_CIRCULATIONAHA_111_040246 crossref_primary_10_1097_HCO_0000000000000708 crossref_primary_10_2106_JBJS_CC_M_00286 crossref_primary_10_1007_s00540_015_2044_6 crossref_primary_10_1007_s10620_015_3538_7 crossref_primary_10_1097_ALN_0000000000004627 crossref_primary_10_1016_j_cardfail_2019_11_027 crossref_primary_10_1093_ejcts_ezs320 crossref_primary_10_1016_j_jacep_2018_08_009 crossref_primary_10_1038_s41598_021_01696_3 crossref_primary_10_1097_MAT_0000000000001297 crossref_primary_10_1016_j_athoracsur_2011_06_081 crossref_primary_10_1097_MAT_0000000000001054 crossref_primary_10_1097_MAT_0000000000001296 crossref_primary_10_1016_j_bpa_2015_04_003 crossref_primary_10_1053_j_jvca_2017_02_184 crossref_primary_10_1097_MAT_0b013e31825b8d36 crossref_primary_10_1213_ANE_0000000000000554 crossref_primary_10_1016_j_jtcvs_2013_08_043 crossref_primary_10_1038_nrcardio_2012_178 crossref_primary_10_1161_CIRCHEARTFAILURE_118_005483 crossref_primary_10_1097_MBC_0b013e32835bfdde crossref_primary_10_1080_17434440_2016_1208557 crossref_primary_10_1093_ejcts_ezu510 crossref_primary_10_1093_ejcts_ezz098 crossref_primary_10_1002_ajh_23836 crossref_primary_10_1016_j_rpth_2024_102506 crossref_primary_10_1111_jocs_14079 crossref_primary_10_1161_CIRCHEARTFAILURE_115_002680 crossref_primary_10_1016_j_amjcard_2013_06_023 crossref_primary_10_1160_th14_02_0148 crossref_primary_10_1016_j_healun_2024_07_017 crossref_primary_10_1007_s10620_015_3810_x crossref_primary_10_1016_j_jacc_2014_08_052 crossref_primary_10_1177_0267659115579714 |
| ContentType | Journal Article |
| Copyright | Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jacc.2010.05.016 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-3597 |
| ExternalDocumentID | 20598466 |
| Genre | Journal Article Comparative Study |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AABVL AACTN AAEDT AAEDW AAIKJ AAKUH AAOAW AAQFI AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABOCM ABWVN ABXDB ACGFO ACGFS ACIUM ACJTP ACPRK ACRPL ADBBV ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEVXI AEXQZ AFCTW AFETI AFFNX AFRAH AFRHN AFTJW AGHFR AGYEJ AHMBA AITUG AJRQY AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GX1 H13 HVGLF HZ~ IHE IXB J1W K-O KQ8 L7B MO0 N9A NPM O-L O9- OA. OAUVE OK1 OL~ OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 QTD RIG ROL RPZ SCC SDF SDG SDP SES SSZ TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YZZ Z5R 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS EFLBG ~HD |
| ID | FETCH-LOGICAL-c585t-87cde59c71db8bbd60e9db6a6431d0e6f7c40b027e979270ec0e3ad85a37cd702 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 454 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000282279400006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1558-3597 |
| IngestDate | Sun Sep 28 07:18:22 EDT 2025 Thu Apr 03 07:09:36 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 15 |
| Language | English |
| License | Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c585t-87cde59c71db8bbd60e9db6a6431d0e6f7c40b027e979270ec0e3ad85a37cd702 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S0735109710020991 |
| PMID | 20598466 |
| PQID | 756659769 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_756659769 pubmed_primary_20598466 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-10-05 |
| PublicationDateYYYYMMDD | 2010-10-05 |
| PublicationDate_xml | – month: 10 year: 2010 text: 2010-10-05 day: 05 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of the American College of Cardiology |
| PublicationTitleAlternate | J Am Coll Cardiol |
| PublicationYear | 2010 |
| References | 20630678 - J Am Coll Cardiol. 2010 Oct 5;56(15):1214-5 |
| References_xml | – reference: 20630678 - J Am Coll Cardiol. 2010 Oct 5;56(15):1214-5 |
| SSID | ssj0006819 |
| Score | 2.5386999 |
| Snippet | The objective of the study was to determine the prevalence of bleeding during continuous-flow left ventricular assist device support and to identify potential... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1207 |
| SubjectTerms | Adolescent Adult Aged Female Follow-Up Studies Heart Transplantation - adverse effects Heart-Assist Devices - adverse effects Hemorrhage - epidemiology Hemorrhage - etiology Humans Intraoperative Complications - blood Intraoperative Complications - epidemiology Intraoperative Complications - etiology Male Middle Aged Prevalence Retrospective Studies Time Factors Treatment Outcome von Willebrand Diseases - epidemiology von Willebrand Diseases - etiology Young Adult |
| Title | Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20598466 https://www.proquest.com/docview/756659769 |
| Volume | 56 |
| WOSCitedRecordID | wos000282279400006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV25TsQwELW4hGi470NT0FpkN4kdVwghEA0rCpC2W_kKAi3OQrLwbfwdM04WKkRBkyLKRFbGmXm238xj7FSankmNdLwnRMazMs-5ypTkypZ9ibcQctsoNiEHg2I4VHcdN6fuaJWzmBgDtass7ZGfScQdCH6FOp-8chKNosPVTkFjni2miGSI0SWHP83CRRF1PTBjFjxF265mpqV3PWtrO2YXNe4UvyPMmGmu1_45xnW22kFMuGjnxAab82GTLd92h-hb7PPCEv3XO3ivAtCGCx0eBwez7gUQhcOBWOxPYVpNa16Oqw948VQlTE4F5ynAQD2dEHyPT0bhLF9DU4EGaoIMkzdqJU6RA6oSzLjNk9AWRsK4Co-c8sL3W2gIugFEpECK92TUxNbrY93WR4Vt9nB9dX95wzsFB25xGdJgqLXO58rKnjOFMU4kXjkjNMKgnku8KKXNEoMrY6-k6svE28Sn2hW5TtFSJv0dthCq4PcYoFVhyiLFFa3NdJqbUqGhVRlCEGVVvs9g5pMR_iF07KGDx080-vbKPttt_TqatJ08Rn0ElwjAxMHfxodsJRIHInfgiC2WGB38MVuy781T_XYSZx5eB3e3X45E6Hk |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acquired+von+Willebrand+syndrome+after+continuous-flow+mechanical+device+support+contributes+to+a+high+prevalence+of+bleeding+during+long-term+support+and+at+the+time+of+transplantation&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Uriel%2C+Nir&rft.au=Pak%2C+Sang-Woo&rft.au=Jorde%2C+Ulrich+P&rft.au=Jude%2C+Brigitte&rft.date=2010-10-05&rft.eissn=1558-3597&rft.volume=56&rft.issue=15&rft.spage=1207&rft_id=info:doi/10.1016%2Fj.jacc.2010.05.016&rft_id=info%3Apmid%2F20598466&rft_id=info%3Apmid%2F20598466&rft.externalDocID=20598466 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-3597&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-3597&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-3597&client=summon |